Indication

Diabetes

Clinical and regulatory intelligence for Diabetes with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Assets: 3

Relevant assets

Dapagliflozin →

Empagliflozin →

Neuropathy →

Relevant companies

Aurobindo Pharma →

Eli Lilly →

Jiangsu Hansoh Pharma →

Recent signals(4)

StrategyJune 19, 2026

Aurobindo Pharma submits ANDA for Empagliflozin and Metformin Hydrochloride

Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for Empagliflozin and Metformin Hydrochloride.

ClinicalJune 18, 2026

Study Compares 3D Printed vs Ready-to-Wear Insoles for Diabetic Neuropathy

A randomized controlled trial is underway to evaluate the effectiveness of 3D printed insoles compared to ready-to-wear insoles in diabetic neuropathy patients.

CompetitiveJune 16, 2026

Lilly's Foundayo shows superior A1C reduction and weight loss in pivotal diabetes trials

Foundayo (orforglipron) demonstrated a 57.1% greater reduction in A1C and significant weight loss compared to oral semaglutide in pivotal trials.

CompetitiveJune 6, 2026

FDA Submission for Dapagliflozin by Jiangsu Hansoh Pharma

Jiangsu Hansoh Pharma has submitted an original application (ANDA216119) for Dapagliflozin, currently under standard review.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

SGLT2 Inhibitor and Biguanide →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.